Recombinant human growth hormone (rhGH) in dialysis patients: update 1995.
The use of recombinant human growth hormone (rhGH) in patients undergoing dialysis has not received substantial investigation. The available data would indicate that short-term growth velocity is improved with rhGH in children undergoing both peritoneal dialysis and hemodialysis. However, definitive assessment awaits long-term controlled studies. Although definitive studies are lacking, it does not appear that there is a differential effect of rhGH in the various dialytic modalities. Compared to patients with chronic renal insufficiency, the response to rhGH treatment in children undergoing dialysis appears inferior; however, definitive data are also lacking. rhGH is effective when administered intraperitoneally; however, long-term studies are required to substantiate efficacy. In summary, despite limited data, rhGH appears to be effective in growth-retarded children undergoing dialysis.
Fine
R N
RN
Department of Pediatrics, State University of New York, Stony Brook, USA.
D002648:Child; D006130:Growth Disorders / Q000209:etiology / Q000628:therapy; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D010530:Peritoneal Dialysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D011994:Recombinant Proteins; D013006:Growth Hormone